Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Baudax Bio, Inc.
BXRXQ.US
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc.
4.838 T
BXRXQ.USMarket value -Rank by Market Cap -/-

Financial Score

18/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking114/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE397.62%A
    • Profit Margin-563.75%E
    • Gross Margin0.00%E
  • Growth ScoreA
    • Revenue YoY217.25%A
    • Net Profit YoY62.17%B
    • Total Assets YoY17.55%A
    • Net Assets YoY93.87%A
  • Cash ScoreB
    • Cash Flow Margin-16.68%D
    • OCF YoY217.25%A
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreE
    • Gearing Ratio105.82%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --